Kavita Israni-Winger, Devon Wasche
Jun 1, 2021
Citations
0
Influential Citations
0
Citations
Journal
The Yale Journal of Biology and Medicine
Abstract
Accessible online at: www.karger.com/ocl To present ifosfamide is an easy job, since this drug has been well known worldwide for more than 20 years. In 1984, I had the opportunity to publish, as co-editor, a booklet on Alkylating Agents, and the ifosfamide discoverer, Dr. Norbert Brock, was among the co-authors [1]. At that time, IFO was a ‘new drug’; nowadays it is a miliary stone drug with still new fascinating fields of application. This prodrug alkylating agent is currently used in the therapy of lymphomas, soft tissue sarcomas, uterine sarcoma, squamous cell carcinoma of the uterine cervix, germ cell tumors, urothelial cancer, and lung, ovary and breast cancer. Another use is represented by marrow-ablative IFO dose to increase tumor cell kill as in Hodgkin’s disease in first or second relapse, and in some types of non-Hodgkin’s lymphomas. The host is rescued with harvested peripheral CD34 cell. I had the opportunity to join some outstanding researchers and clinicians to critically report their experience of the drug, and experts to analyze the current literature. The supplement includes firstly pharmacology, toxicity, IFO-based combination chemotherapy, effects on immunosurveillance and continuous infusion, treatments of different cancers follow: head and neck cancer, thymic neoplasm, small cell lung cancer, non-small cell lung cancer, breast cancer, ovarian tumors, cervical cancer, urologic cancer, germ cell tumors, soft-tissue sarcoma. Finally, the IFO therapies of hematological malignancies are described: hematological malignancies of adults, multiple myeloma and pediatric solid tumors. This supplement to Oncology will represent, I do hope, a bench booklet for those who utilize IFO. All the scientific material was presented at the Meeting on Ifosfamide held in Padua, Abano Terme, Italy (Ifosfamide: A Milestone Drug, February 17–18, 2003), under the auspices of the Postgraduate School of Radiotherapy (University of Padua) and Oncology (University of Udine). On that occasion, Nobert Brock, Lawrence Einhorn and Jean Klastersky were awarded with the ‘Sigillo di Padova’ (Padua Seal) for their high merits in the field of cancer therapy. The Seal was presented by the Lord Mayor of Padua (Mrs. Giustina Mistrello Destro), the University of Padua Pro-Rector Foreign Affairs, Prof. Giorgio Palù, MD, and myself as the General Consultant of Oncology, ULSS 16 – Padova. The ceremony was attended by the General Director of the University General Hospital of Padua, Dr. Adriano Cestrone. The main sponsor of the meeting was the producer of IFO, Baxter, Italy, whom we gratefully thank. Present work was partly supported by AOI (Associazione Oncologica Italiana), Padova, Italy. Finally, we thank Dr. Luisa Cartei, BA, for her help and advice in planning the Meeting. Giuseppe Cartei